The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Open accessAbstract
INTRODUCTION: Research over the past three decades has identified p53 as a multi-functional transcription factor. p53 influences myriad, highly diverse cellular processes, and represents one of the most important and extensively studied tumor suppressors. Activated by various stresses, p53 blocks cancer progression by provoking transient or permanent growth arrest, by enabling DNA repair, or by advancing cellular death programs. This anti-cancer activity profile, together with genomic and mutational analyses documenting inactivation of p53 in more than 50% of human cancers, motivated drug development efforts to (re-) activate p53 in established tumors. AREAS COVERED: The complexities of p53 signaling in cancer are summarized, including current strategies and challenges to restore p53's tumor suppressive function in established tumors, to inactivate p53 inhibitors, and to restore wild type function of p53 mutant proteins. EXPERT OPINION: p53 represents an attractive target for the development of anti-cancer therapies. Whether p53 is 'druggable', however, remains an area of active research and discussion, as p53 has pro-survival functions and chronic p53 activation accelerates aging, which may compromise the long-term homeostasis of an organism. The complex biology and dual functions of p53 in cancer prevention and age-related cellular responses pose significant challenges to the development of p53-targeting cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Hematopoiesis: An Evolving Paradigm for Stem Cell Biology
Orkin, S. H., & Zon, L. I. (2008) · Cell · doi:10.1016/j.cell.2008.01.025 · Cited by 2,570
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 1×
“What are the molecular parameters that determine the cellular fate of transient cell cycle arrest versus senescence? It may depend on additional signals that cooperate with p53, such as Rb-induced senescence-associated heterochromatin foci to silence E2F target genes, as coactivation of Rb--E2F and p53 axes permanentl…”
BackgroundTP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Identified in the 1970s as a binding partner for the SV40 tumor virus oncoprotein large T antigen and an important target for tumorigenic processes induced by DNA tumor viruses [2-5], research in the late 1980s and 1990s validated p53 as a tumor suppressor gene, as p53 mutations were found in up to 50% of human cancer…”
BackgroundMice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“[36,37] linked p53-directed transcriptomic changes of apoptosis modulators to cytoplasmic, transcription-independent functions of p53, as p53-dependent genotoxic insult induced PUMA, which subsequently displaced p53 from an cytosolic, inhibitory p53:Bcl-xL complex.”
BackgroundRestoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Confirming important roles of p53 in cancer suppression, these studies showed that re-activation of p53 in established tumors can temporarily stop tumor growth; the precise cellular mechanism is cancer-specific, as lymphomas die by apoptosis, whereas p53 restoration in sarcomas and liver carcinomas leads to growth arr…”
Backgroundp53 Regulates Mitochondrial Respiration
Matoba, S., Kang, J.-G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006) · Science · doi:10.1126/science.1126863 · Cited by 1,650
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“5 million compounds identified the carbazole PhiKan083 [1-(9-ethyl9H-carbazole-3-yl)-N-methylmethanamine] as a small molecule that selectively interacted with and stabilized the p53 Y220C mutant, one of the ten most prevalent p53 mutations targeting the DNA binding domain [166].”
Backgroundp53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 1×
“In addition, mice expressing a carboxy-terminal, constitutively active p53 mutant exhibited a premature aging phenotype, including organ atrophy, osteoporosis, and reduced life span [102].”
BackgroundActivation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
Epidermal homeostasis: a balancing act of stem cells in the skin
Blanpain, C., & Fuchs, E. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2636 · Cited by 1,270
Radiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242 · cited 1×
“Critical roles for p21 in G1/S transition have been validated in p21-deficient MEFs and colon cancer cells, exhibiting deficiencies in DNA damage-induced G1 arrest [55-57].”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
Bypass of Senescence After Disruption of p21 CIP1/WAF1 Gene in Normal Diploid Human Fibroblasts
Brown, J. P., Wei, W., & Sedivy, J. M. (1997) · Science · doi:10.1126/science.277.5327.831 · Cited by 804
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Glycolytic Enzymes Can Modulate Cellular Life Span
Kondoh, H., Lleonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez, D., Carnero, A., & Beach, D. (2005) · Cancer Research · doi:10.1158/0008-5472.177.65.1 · Cited by 647
Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response
Chen, W., Sun, Z., Wang, X.-J., Jiang, T., Huang, Z., Fang, D., & Zhang, D. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.029 · Cited by 638 · cited 1×
“In addition to the p53-TIGAR signaling arm, additional p53-instigated survival programs have been identified that protect cells toward reactive oxygen species (ROS), including p53-dependent activation of sestrins [87], p53INP1 signaling [88], and the p21--Nrf2 axis as a master regulatory pathway orchestrating complex…”
BackgroundA novel role for high-mobility group A proteins in cellular senescence and heterochromatin formation
Narita, M., Narita, M., Krizhanovsky, V., Nuñez, S., Chicas, A., Hearn, S. A., Myers, M. P., & Lowe, S. W. (2006) · Cell · doi:10.1016/j.cell.2006.05.052 · Cited by 629
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Transcriptional Regulation by P53
Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569
Cancer and ageing: rival demons?
Campisi, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1073 · Cited by 512 · cited 1×
“6 p53, aging, and stem cells Cancer is an age-related disease [97,98].”
BackgroundDelayed ageing through damage protection by the Arf/p53 pathway
Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J. M., Viña, J., Blasco, M. A., & Serrano, M. (2007) · Nature · doi:10.1038/nature05949 · Cited by 466
The p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374
The multiple levels of regulation by p53 ubiquitination
Lee, J. T., & Gu, W. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.77 · Cited by 289
Monoubiquitylation promotes mitochondrial p53 translocation
Marchenko, N. D., Wolff, S., Erster, S., Becker, K., & Moll, U. M. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601560 · Cited by 286
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
p21 Inhibits Thr161 Phosphorylation of Cdc2 to Enforce the G2 DNA Damage Checkpoint
Smits, V. A. J., Klompmaker, R., Vallenius, T., Rijksen, G., Mäkelä, T. P., & Medema, R. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005437200 · Cited by 221
p21-Mediated Nuclear Retention of Cyclin B1-Cdk1 in Response to Genotoxic Stress
Charrier-Savournin, F. B., Château, M.-T., Gire, V., Sedivy, J., Piette, J., & Dulić, V. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-12-0871 · Cited by 202
Identification and Characterization of the First Small Molecule Inhibitor of MDMX
Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198 · cited 9×
“Mdm2 is an E3 ubiquitin ligase that targets p53 target genes Mdm2 Mdm4 p53 p53 p53 p53* Rx Rx PRIMA-1MET CP31398 PhiKan083 MIRA-3 STIMA-1 SCH529074 Ellipticine RETRA p53R3 WR1065 Nutlins Sulfonamide I NSC66811 Terphenyl 14 TDP665759 TDP521252 MI-219/-319 PXn727/822 Isoindolinone 74a SJ-172550 XI-006 RITA JNJ-26854165…”
BackgroundInfluentialp53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site
Liu, X., Yue, P., Khuri, F. R., & Sun, S.-Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1195 · Cited by 184
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182
Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163
Genetics of Longevity and Aging
Vijg, J., & Suh, Y. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104617 · Cited by 142
Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., & Gabrilovich, D. I. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.484801 · Cited by 126
Increased p53 activity does not accelerate telomere‐driven ageing
García‐Cao, I., García‐Cao, M., Tomás‐Loba, A., Martin‐Caballero, J., Flores, J. M., Klatt, P., Blasco, M. A., & Serrano, M. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400667 · Cited by 102
Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91
Tabe, Y., Sebasigari, D., Jin, L., Rudelius, M., Davies-Hill, T., Miyake, K., Miida, T., Pittaluga, S., & Raffeld, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0399 · Cited by 83
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., Janicot, M., Bourhis, J., & Deutsch, E. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.011 · Cited by 54 · cited 1×
“Candidates include reactivation of p53 and induction of tumor cell apoptosis (RITA), which showed antitumor effects in murine colon cancer models by inducing conformational changes in p53 thereby preventing interaction with Mdm proteins [184], and the tryptamine derivate JNJ-26854165, which blocked p53 proteasomal deg…”
BackgroundRemoving all obstacles: A critical role for p53 in promoting tissue renewal
Schoppy, D. W., Ruzankina, Y., & Brown, E. J. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11194 · Cited by 32 · cited 1×
“In line with a tumor suppressive, pro-death and anti-proliferative role of p53, deficiency in p53 was shown to attenuate profound defects in tissue homeostasis caused by mutations in DNA repair genes [101].”
BackgroundInitial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program
Smith, M. A., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Maris, J. M., Keir, S. T., Morton, C. L., Reynolds, C. P., Kang, M. H., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.23319 · Cited by 26 · cited 1×
“Candidates include reactivation of p53 and induction of tumor cell apoptosis (RITA), which showed antitumor effects in murine colon cancer models by inducing conformational changes in p53 thereby preventing interaction with Mdm proteins [184], and the tryptamine derivate JNJ-26854165, which blocked p53 proteasomal deg…”
Background
Research works printed but not linked: 136
- Vousden KH, 2007, Nat Rev Mol Cell Biol, 8, 275, 10.1038/nrm2147 · DOI · Paper page
- Lane DP, 1979, Nature, 278, 261, 10.1038/278261a0 · DOI · Paper page
- 10.1016/0092-8674(82)90356-7 · DOI · Paper page
- Scheffner M, 1990, Cell, 63, 1129, 10.1016/0092-8674(90)90409-8 · DOI · Paper page
- 10.1101/cshperspect.a001016 · DOI · Paper page
- Yonish-Rouach E, 1991, Nature, 352, 345, 10.1038/352345a0 · DOI · Paper page
- Clarke AR, 1993, Nature, 362, 849, 10.1038/362849a0 · DOI · Paper page
- Lowe SW, 1993, Cell, 74, 957, 10.1016/0092-8674(93)90719-7 · DOI · Paper page
- Sheikh MS, 1998, Cancer Res, 58, 1593
- Peter ME, 2003, Cell Death Differ, 10, 26, 10.1038/sj.cdd.4401186 · DOI · Paper page
- Ehrhardt H, 2008, Oncogene, 27, 783, 10.1038/sj.onc.1210666 · DOI
- Attardi LD, 2000, Genes Dev, 14, 704, 10.1101/gad.14.6.704 · DOI · Paper page
- Davies L, 2009, J Cell Mol Med, 13, 1995, 10.1111/j.1582-4934.2008.00590.x · DOI
- Stegh AH, 2001, Cardiol Clin, 19, 13, 10.1016/S0733-8651(05)70192-2 · DOI
- Youle RJ, 2008, Nat Rev Mol Cell Biol, 9, 47, 10.1038/nrm2308 · DOI · Paper page
- Miyashita T, 1995, Cell, 80, 293, 10.1016/0092-8674(95)90513-8 · DOI · Paper page
- Yu J, 2001, Mol Cell, 7, 673, 10.1016/S1097-2765(01)00213-1 · DOI · Paper page
- Nakano K, 2001, Mol Cell, 7, 683, 10.1016/S1097-2765(01)00214-3 · DOI · Paper page
- Han J, 2001, Proc Natl Acad Sci USA, 98, 11318, 10.1073/pnas.201208798 · DOI · Paper page
- 10.1126/science.284.5411.156 · DOI · Paper page
- Jeffers JR, 2003, Cancer Cell, 4, 321, 10.1016/S1535-6108(03)00244-7 · DOI · Paper page
- Chipuk JE, 2003, Cancer Cell, 4, 371, 10.1016/S1535-6108(03)00272-1 · DOI · Paper page
- Caelles C, 1994, Nature, 370, 220, 10.1038/370220a0 · DOI · Paper page
- Johnson TM, 2008, Proc Natl Acad Sci USA, 105, 1215, 10.1073/pnas.0706764105 · DOI
- Chipuk JE, 2005, Science, 309, 1732, 10.1126/science.1114297 · DOI · Paper page
- Mihara M, 2003, Mol Cell, 11, 577, 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
- Leu JI, 2004, Nat Cell Biol, 6, 443, 10.1038/ncb1123 · DOI · Paper page
- 10.4161/cc.7.18.6759 · DOI
- Stegh AH, 2008, Proc Natl Acad Sci USA, 105, 10703, 10.1073/pnas.0712034105 · DOI
- Stegh AH, 2007, Genes Dev, 21, 98, 10.1101/gad.1480007 · DOI
- Stegh AH, 2010, Genes Dev, 24, 2194, 10.1101/gad.1924710 · DOI
- 10.4161/cc.10.1.14365 · DOI
- Kumar S, 2009, Nat Rev Cancer, 9, 897, 10.1038/nrc2745 · DOI
- Tinel A, 2004, Science, 304, 843, 10.1126/science.1095432 · DOI · Paper page
- Lin Y, 2000, Nat Genet, 26, 122, 10.1038/79102 · DOI · Paper page
- Zong WX, 2006, Genes Dev, 20, 1, 10.1101/gad.1376506 · DOI · Paper page
- Yuan J, 2010, Genes Dev, 24, 2592, 10.1101/gad.1984410 · DOI · Paper page
- Tu HC, 2009, Proc Natl Acad Sci USA, 106, 1093, 10.1073/pnas.0808173106 · DOI
- Giono LE, 2006, J Cell Physiol, 209, 13, 10.1002/jcp.20689 · DOI · Paper page
- Sherr CJ, 1994, Cell, 79, 551, 10.1016/0092-8674(94)90540-1 · DOI · Paper page
- el-Deiry WS, 1994, Cancer Res, 54, 1169
- el-Deiry WS, 1993, Cell, 75, 817, 10.1016/0092-8674(93)90500-P · DOI · Paper page
- Waldman T, 1995, Cancer Res, 55, 5187
- Rohaly G, 2005, Cell, 122, 21, 10.1016/j.cell.2005.04.032 · DOI
- St Clair S, 2004, Mol Cell, 16, 725, 10.1016/j.molcel.2004.11.002 · DOI · Paper page
- Hermeking H, 1997, Mol Cell, 1, 3, 10.1016/S1097-2765(00)80002-7 · DOI · Paper page
- Ando T, 2001, J Biol Chem, 276, 42971, 10.1074/jbc.M106460200 · DOI · Paper page
- Zhan Q, 1999, Oncogene, 18, 2892, 10.1038/sj.onc.1202667 · DOI · Paper page
- Jin S, 2000, J Biol Chem, 275, 16602, 10.1074/jbc.M000284200 · DOI · Paper page
- Nezi L, 2009, Curr Opin Cell Biol, 21, 785, 10.1016/j.ceb.2009.09.007 · DOI · Paper page
- Cross SM, 1995, Science, 267, 1353, 10.1126/science.7871434 · DOI · Paper page
- Di Leonardo A, 1997, Cancer Res, 57, 1013
- Fukasawa K, 1996, Science, 271, 1744, 10.1126/science.271.5256.1744 · DOI · Paper page
- 10.1128/MCB.18.2.1055 · DOI · Paper page
- Smith ML, 1994, Science, 266, 1376, 10.1126/science.7973727 · DOI · Paper page
- Smith ML, 1996, Oncogene, 13, 2255
- Janus F, 1999, Cell Mol Life Sci, 55, 12, 10.1007/s000180050266 · DOI
- Gottlieb E, 2010, Cold Spring Harb Perspect Biol, 2, a001040, 10.1101/cshperspect.a001040 · DOI · Paper page
- Ma W, 2007, J Bioenerg Biomembr, 39, 243, 10.1007/s10863-007-9083-0 · DOI
- Kulawiec M, 2009, J Carcinog, 8, 8, 10.4103/1477-3163.50893 · DOI
- Lebedeva MA, 2009, Biochim Biophys Acta, 1787, 328, 10.1016/j.bbabio.2009.01.004 · DOI · Paper page
- Okamura S, 1999, Oncol Res, 11, 281
- Schwartzenberg-Bar-Yoseph F, 2004, Cancer Res, 64, 2627, 10.1158/0008-5472.CAN-03-0846 · DOI · Paper page
- Kawauchi K, 2008, Nat Cell Biol, 10, 611, 10.1038/ncb1724 · DOI · Paper page
- Bensaad K, 2007, Trends Cell Biol, 17, 286, 10.1016/j.tcb.2007.04.004 · DOI · Paper page
- Li H, 2009, J Biol Chem, 284, 1748, 10.1074/jbc.M807821200 · DOI
- Vousden KH, 2009, Biochem Soc Trans, 37, 511, 10.1042/BST0370511 · DOI
- Muniyappa H, 2009, J Biol Chem, 284, 17069, 10.1074/jbc.M109.008557 · DOI
- Budanov AV, 2004, Science, 304, 596, 10.1126/science.1095569 · DOI · Paper page
- Cano CE, 2009, Cancer Res, 69, 219, 10.1158/0008-5472.CAN-08-2320 · DOI
- Hayflick L, 1965, Exp Cell Res, 37, 614, 10.1016/0014-4827(65)90211-9 · DOI · Paper page
- Zilfou JT, 2009, Cold Spring Harb Perspect Biol, 1, a001883, 10.1101/cshperspect.a001883 · DOI · Paper page
- Gorgoulis VG, 2003, EMBO J, 22, 1567, 10.1093/emboj/cdg157 · DOI
- Dumble M, 2007, Blood, 109, 1736, 10.1182/blood-2006-03-010413 · DOI · Paper page
- Junttila MR, 2010, Nature, 468, 567, 10.1038/nature09526 · DOI · Paper page
- Feldser DM, 2010, Nature, 468, 572, 10.1038/nature09535 · DOI · Paper page
- 10.1093/carcin/23.12.2011 · DOI · Paper page
- 10.1002/(SICI)1097-0215(19960917)67:6<808::AID-IJC9>3.0.CO;2-V · doi:10.1002/(sici)1097-0215(19960917)67:6<808::aid-ijc9>3.0.co;2-v
- Gomez-Manzano C, 1996, Cancer Res, 56, 694
- Gomez-Manzano C, 1997, J Natl Cancer Inst, 89, 1036, 10.1093/jnci/89.14.1036 · DOI
- 10.1097/00006123-199911000-00016 · DOI
- Li H, 1999, Clin Cancer Res, 5, 637
- Lang FF, 2003, J Clin Oncol, 21, 2508, 10.1200/JCO.2003.11.138 · DOI · Paper page
- 10.1158/1078-0432.CCR-09-1044 · DOI
- Zeimet AG, 2003, Lancet Oncol, 4, 415, 10.1016/S1470-2045(03)01139-2 · DOI · Paper page
- Nemunaitis J, 2000, Cancer Res, 60, 6359
- Shi J, 2009, Curr Opin Mol Ther, 11, 547
- 10.1007/s00432-009-0701-6 · DOI
- Tian G, 2009, Anticancer Drugs, 20, 389, 10.1097/CAD.0b013e32832a2df9 · DOI
- 10.1158/1535-7163.MCT-07-0125 · DOI
- 10.3892/or_00001018 · DOI
- Pan JJ, 2009, J Clin Oncol, 27, 799, 10.1200/JCO.2008.18.9670 · DOI
- Li Y, 2009, Clin Cancer Res, 15, 6724, 10.1158/1078-0432.CCR-09-1296 · DOI
- Keedy V, 2008, J Clin Oncol, 26, 4166, 10.1200/JCO.2007.15.6927 · DOI
- Ulasov IV, 2007, Hum Gene Ther, 18, 118, 10.1089/hum.2006.146 · DOI
- Bischoff JR, 1996, Science, 274, 373, 10.1126/science.274.5286.373 · DOI · Paper page
- Khuri FR, 2000, Nat Med, 6, 879, 10.1038/78638 · DOI · Paper page
- O'Shea CC, 2004, Cancer Cell, 6, 611, 10.1016/j.ccr.2004.11.012 · DOI · Paper page
- Chiocca EA, 2004, Mol Ther, 10, 958, 10.1016/j.ymthe.2004.07.021 · DOI · Paper page
- 10.2174/156800907780058862 · DOI
- Tyler MA, 2009, Gene Ther, 16, 262, 10.1038/gt.2008.165 · DOI
- 10.1634/stemcells.2007-0758 · DOI · Paper page
- Sherr CJ, 2006, Nat Rev Cancer, 6, 663, 10.1038/nrc1954 · DOI · Paper page
- 10.4161/cc.3.4.801 · DOI · Paper page
- Kojima K, 2005, Blood, 106, 3150, 10.1182/blood-2005-02-0553 · DOI · Paper page
- Secchiero P, 2009, Blood, 113, 4300, 10.1182/blood-2008-11-187708 · DOI
- Carter BZ, 2010, Blood, 115, 306, 10.1182/blood-2009-03-212563 · DOI
- Galatin PS, 2004, J Med Chem, 47, 4163, 10.1021/jm034182u · DOI
- Lu Y, 2006, J Med Chem, 49, 3759, 10.1021/jm060023+ · DOI
- Yin H, 2005, Angew Chem Int Ed Engl, 44, 2704, 10.1002/anie.200462316 · DOI · Paper page
- 10.1158/1535-7163.MCT-05-0199 · DOI · Paper page
- Essmann F, 2011, Br J Pharmacol
- Hardcastle IR, 2011, J Med Chem, 54, 1233, 10.1021/jm1011929 · DOI
- 10.1021/jm0601194 · DOI
- 10.4161/cc.1.6.259 · DOI
- Sur S, 2009, Proc Natl Acad Sci USA, 106, 3964, 10.1073/pnas.0813333106 · DOI · Paper page
- 1998, Crit Rev Immunol, 18, 29, 10.1615/CritRevImmunol.v18.i1-2.40 · DOI
- 10.1158/1078-0432.CCR-08-2227 · DOI · Paper page
- 10.1038/onc.2008.249 · DOI
- Bykov VJ, 2005, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
- Wiman KG, 2010, Oncogene, 29, 4245, 10.1038/onc.2010.188 · DOI · Paper page
- Boeckler FM, 2008, Proc Natl Acad Sci USA, 105, 10360, 10.1073/pnas.0805326105 · DOI · Paper page
- 10.1101/sqb.2005.70.049 · DOI
- Demma M, 2010, J Biol Chem, 285, 10198, 10.1074/jbc.M109.083469 · DOI
- Kravchenko JE, 2008, Proc Natl Acad Sci USA, 105, 6302, 10.1073/pnas.0802091105 · DOI · Paper page
- North S, 2002, Mol Carcinog, 33, 181, 10.1002/mc.10038 · DOI
- Weinmann L, 2008, Cell Death Differ, 15, 718, 10.1038/sj.cdd.4402301 · DOI
- Belyi VA, 2010, Cold Spring Harb Perspect Biol, 2, a001198, 10.1101/cshperspect.a001198 · DOI · Paper page
- 10.1038/onc.2010.266 · DOI
- Saddler C, 2008, Blood, 111, 1584, 10.1182/blood-2007-09-112698 · DOI
- Calabro V, 2004, Mol Cell Biol, 24, 8529, 10.1128/MCB.24.19.8529-8540.2004 · DOI
- 10.1074/jbc.C600147200 · DOI · Paper page
- Wang H, 2011, Mol Cancer Ther, 10, 69, 10.1158/1535-7163.MCT-10-0581 · DOI · Paper page
- Issaeva N, 2004, Nat Med, 10, 1321, 10.1038/nm1146 · DOI · Paper page
- Smith MA, 2011, Pediatr Blood Cancer
- Bernal F, 2007, J Am Chem Soc, 129, 2456, 10.1021/ja0693587 · DOI · Paper page
Cited by
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
The lncRNA Neat1 promotes activation of inflammasomes in macrophages
Zhang, P., Cao, L., Zhou, R., Yang, X., & Wu, M. (2019) · Nature Communications · doi:10.1038/s41467-019-09482-6 · Cited by 499
Programmed cell death in aging
Tower, J. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.04.002 · Cited by 426
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163
Metadata
- Authors
- Stegh, A. H.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2012-01
- Volume
- 16
- Issue
- 1
- Pages
- 67-83
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W1980250100
- Cited by
- 194
- References
- 57
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.